Sosei appoints Peter Bains as COO and CEO-elect
pharmafile | March 22, 2016 | Appointment | Research and Development |
Japan’s Sosei Group has announced the appointment of Syngene chief executive Peter Bains as representative executive officer and chief operating officer (COO) effective from April 1, 2016, also positioning the former Heptares director as chief executive elect.
Mr Bains will assume responsibility for all operational activities of Sosei and will report to group chairman, president and chief executive Shinichi Tamura before Tamura moves to a role as executive chairman in June 2016.
Bains, 58, has some 30 years of experience in pharma, encompassing strategic and operational leadership expertise across global geographies, functions and business segments.
He spent the bulk of this time, 23 years, at GSK, where he held multiple senior roles including general manager of China, vice president of International Business Development, head of Global Marketing and senior vice president of International Commercial Development.
From 2009, he has been a consultant specialising in supporting strategic growth opportunities in small and medium-sized innovation-based life science companies. He currently serves as a non-executive director at Sosei Group, in addition to his role as chief executive at Syngene, a subsidiary of Biocon. Bains is retiring ftrom this role this month.
Commenting on the appointment, Shinichi Tamura says: “I am delighted to announce Mr Bains as my successor in leading Sosei Group into its next phase of evolution and growth. Mr Bains has served Sosei for the past five years in his capacity as a non-executive director, and in this role has worked closely with me and the Board to shape Sosei’s evolving strategy to become a global biopharmaceutical business. Along with his deep insight of our Group and its activities, Mr Bains brings a strong track record of successful leadership and operational experience in the biopharmaceutical sector that will serve to strengthen our company’s leadership and capabilities in the dynamic and exciting future we are planning.”
Bains adds: “I am both personally honoured and also extremely excited at the prospect of taking up these new roles and I would like to thank Mr Tamura and the Sosei Board for their trust and support. Sosei Group is now at a very dynamic point in its history as it seeks to expand its operational scope and scale, and I am looking forward to contributing to its rapid evolution into a truly global biopharmaceutical company.”
